- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Companies in the news are: MESO, ODP, LLY, AZZ
Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF Phase 3 trial in patients with chronic heart failure. The presentation materials have been lodged with the ASX, and Mesoblast’s presentation at the H.C. Wainwright Virtual BioConnect 2021 Conference can be accessed at h...
Mesoblast (NASDAQ: MESO) started the week on a strong note. Investors bid up Mesoblast's stock today because the company announced additional positive results from a clinical trial for rexlemestrocel-L, one of its leading pipeline candidates. Patients with chronic heart failure are at a higher risk of heart attack, stroke, and other cardiac-related illnesses.
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (REVASCOR®) or control sham. A single dose of rexlemestrocel-L resulted in substantial and durable reduct...
One thing we could say about the analysts on Mesoblast Limited ( ASX:MSB ) - they aren't optimistic, having just made a...
Investors are losing confidence because the company disappointed in a late-stage trial for the second time this week.